SG11202006300XA - Heterocyclyl-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors - Google Patents
Heterocyclyl-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitorsInfo
- Publication number
- SG11202006300XA SG11202006300XA SG11202006300XA SG11202006300XA SG11202006300XA SG 11202006300X A SG11202006300X A SG 11202006300XA SG 11202006300X A SG11202006300X A SG 11202006300XA SG 11202006300X A SG11202006300X A SG 11202006300XA SG 11202006300X A SG11202006300X A SG 11202006300XA
- Authority
- SG
- Singapore
- Prior art keywords
- ghrelin
- heterocyclyl
- goat
- inhibitors
- acyl transferase
- Prior art date
Links
- 241000283707 Capra Species 0.000 title 1
- 102100038752 Ghrelin O-acyltransferase Human genes 0.000 title 1
- 101710205760 Ghrelin O-acyltransferase Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- RWXCVESEMJNNMF-UHFFFAOYSA-N oxadiazolo[5,4-b]pyridine Chemical class C1=CN=C2ON=NC2=C1 RWXCVESEMJNNMF-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18154828 | 2018-02-02 | ||
| PCT/EP2019/051993 WO2019149659A1 (en) | 2018-02-02 | 2019-01-28 | Heterocyclyl-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202006300XA true SG11202006300XA (en) | 2020-07-29 |
Family
ID=61157053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202006300XA SG11202006300XA (en) | 2018-02-02 | 2019-01-28 | Heterocyclyl-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US11319310B2 (en) |
| EP (1) | EP3746450B1 (en) |
| JP (1) | JP7150032B2 (en) |
| KR (1) | KR20200118124A (en) |
| CN (1) | CN111655699B (en) |
| AU (1) | AU2019215709A1 (en) |
| BR (1) | BR112020014320A2 (en) |
| CA (1) | CA3087827A1 (en) |
| CL (1) | CL2020001908A1 (en) |
| CO (1) | CO2020009179A2 (en) |
| CR (1) | CR20200331A (en) |
| EA (1) | EA202091804A1 (en) |
| EC (1) | ECSP20050791A (en) |
| IL (1) | IL276137A (en) |
| JO (1) | JOP20200191A1 (en) |
| MA (1) | MA53074A (en) |
| MX (1) | MX2020008116A (en) |
| PE (1) | PE20210175A1 (en) |
| PH (1) | PH12020551169A1 (en) |
| SG (1) | SG11202006300XA (en) |
| WO (1) | WO2019149659A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3494120T (en) | 2016-08-05 | 2021-05-26 | Boehringer Ingelheim Int | Oxadiazolopyridine derivates for use as ghrelin o-acyl transferase (goat) inhibitors |
| EP3746449B1 (en) * | 2018-02-02 | 2022-03-30 | Boehringer Ingelheim International GmbH | Pyrazole- and indazole-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors |
| CR20200329A (en) | 2018-02-02 | 2020-09-04 | Boehringer Ingelheim Int | Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors |
| JOP20200190A1 (en) | 2018-02-02 | 2020-07-29 | Boehringer Ingelheim Int | Benzyl-, (pyridin-3-yl)methyl- or (pyridin-4-yl)methyl-substituted oxadiazolopyridine derivatives as ghrelin o-acyl transferase (goat) inhibitors |
| WO2021233884A1 (en) | 2020-05-22 | 2021-11-25 | Boehringer Ingelheim International Gmbh | Continuous process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate |
| CN115884974A (en) * | 2020-05-22 | 2023-03-31 | 勃林格殷格翰国际有限公司 | Process for preparing alkyl 7-amino-5-methyl- [1,2,5] oxadiazolo [3,4-b ] pyridinecarboxylic acid esters |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004082383A1 (en) | 2003-03-17 | 2004-09-30 | Basf Aktiengesellschaft | Use of triazolopyrimidines for combating nematode diseases of plants |
| WO2008101017A2 (en) | 2007-02-15 | 2008-08-21 | Indiana Unversity Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| ATE520714T1 (en) | 2007-06-15 | 2011-09-15 | Zealand Pharma As | GLUCAGON ANALOGUE |
| BRPI0823377A2 (en) | 2008-12-15 | 2016-09-27 | Zealand Pharma As | glucagon analogs |
| BRPI0823376A2 (en) | 2008-12-15 | 2015-06-16 | Zealand Pharma As | Glucagon analogs |
| BRPI0823378A2 (en) | 2008-12-15 | 2019-09-24 | Zealand Pharma As | glucagon analogs |
| ES2439499T3 (en) | 2008-12-15 | 2014-01-23 | Zealand Pharma A/S | Glucagon analogues |
| KR101809024B1 (en) | 2009-07-13 | 2017-12-14 | 질랜드 파마 에이/에스 | Acylated glucagon analogues |
| AR081975A1 (en) | 2010-06-23 | 2012-10-31 | Zealand Pharma As | GLUCAGON ANALOGS |
| MX2012014961A (en) | 2010-06-24 | 2013-02-26 | Zealand Pharma As | Glucagon analogues. |
| JP2015502380A (en) | 2011-12-23 | 2015-01-22 | ジーランド ファーマ アクティーゼルスカブ | Glucagon analog |
| EP2838891B1 (en) | 2012-02-24 | 2017-08-02 | Takeda Pharmaceutical Company Limited | Aromatic ring compound as ghrelin o-acyltransferase inhibitor |
| ES2784223T3 (en) * | 2012-06-20 | 2020-09-23 | Univ Virginia Patent Foundation | Compositions and procedures for regulating glucose homeostasis and insulin action |
| TWI608013B (en) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | Glucagon analogues |
| UA118034C2 (en) * | 2013-11-14 | 2018-11-12 | Елі Ліллі Енд Компані | Substituted piperidyl-ethyl-pyrimidine as ghrelin o-acyl transferase inhibitor |
| WO2016044467A1 (en) | 2014-09-17 | 2016-03-24 | The Regents Of The University Of California | Small lipopeptidomimetic inhibitors of ghrelin o-acyl transferase |
| EP3250569B1 (en) * | 2015-01-30 | 2019-01-09 | Boehringer Ingelheim International GmbH | Aldosterone synthase inhibitors |
| AR104673A1 (en) | 2015-04-15 | 2017-08-09 | Lilly Co Eli | GRELINA INHIBITORS O-ACILTRANSFERASA |
| AR104672A1 (en) | 2015-04-15 | 2017-08-09 | Lilly Co Eli | GRELINA INHIBITORS O-ACILTRANSFERASA |
| PT3494120T (en) | 2016-08-05 | 2021-05-26 | Boehringer Ingelheim Int | Oxadiazolopyridine derivates for use as ghrelin o-acyl transferase (goat) inhibitors |
-
2019
- 2019-01-28 MX MX2020008116A patent/MX2020008116A/en unknown
- 2019-01-28 KR KR1020207025418A patent/KR20200118124A/en unknown
- 2019-01-28 EA EA202091804A patent/EA202091804A1/en unknown
- 2019-01-28 EP EP19702085.2A patent/EP3746450B1/en active Active
- 2019-01-28 JO JOP/2020/0191A patent/JOP20200191A1/en unknown
- 2019-01-28 CA CA3087827A patent/CA3087827A1/en not_active Abandoned
- 2019-01-28 BR BR112020014320-0A patent/BR112020014320A2/en not_active Application Discontinuation
- 2019-01-28 CR CR20200331A patent/CR20200331A/en unknown
- 2019-01-28 WO PCT/EP2019/051993 patent/WO2019149659A1/en unknown
- 2019-01-28 JP JP2020541870A patent/JP7150032B2/en active Active
- 2019-01-28 SG SG11202006300XA patent/SG11202006300XA/en unknown
- 2019-01-28 PE PE2020001163A patent/PE20210175A1/en unknown
- 2019-01-28 CN CN201980010384.6A patent/CN111655699B/en active Active
- 2019-01-28 MA MA053074A patent/MA53074A/en unknown
- 2019-01-28 AU AU2019215709A patent/AU2019215709A1/en not_active Abandoned
- 2019-01-28 US US16/966,489 patent/US11319310B2/en active Active
-
2020
- 2020-07-19 IL IL276137A patent/IL276137A/en unknown
- 2020-07-21 CL CL2020001908A patent/CL2020001908A1/en unknown
- 2020-07-24 CO CONC2020/0009179A patent/CO2020009179A2/en unknown
- 2020-07-31 PH PH12020551169A patent/PH12020551169A1/en unknown
- 2020-08-24 EC ECSENADI202050791A patent/ECSP20050791A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3087827A1 (en) | 2019-08-08 |
| CL2020001908A1 (en) | 2020-10-30 |
| PH12020551169A1 (en) | 2021-05-31 |
| JOP20200191A1 (en) | 2020-07-29 |
| EP3746450B1 (en) | 2022-03-16 |
| CR20200331A (en) | 2020-09-03 |
| JP2021512112A (en) | 2021-05-13 |
| AU2019215709A1 (en) | 2020-07-16 |
| PE20210175A1 (en) | 2021-01-29 |
| CN111655699B (en) | 2023-07-14 |
| MA53074A (en) | 2021-05-12 |
| CO2020009179A2 (en) | 2020-07-31 |
| MX2020008116A (en) | 2020-09-25 |
| JP7150032B2 (en) | 2022-10-07 |
| ECSP20050791A (en) | 2020-09-30 |
| KR20200118124A (en) | 2020-10-14 |
| BR112020014320A2 (en) | 2020-12-08 |
| US20210040077A1 (en) | 2021-02-11 |
| IL276137A (en) | 2020-09-30 |
| EP3746450A1 (en) | 2020-12-09 |
| WO2019149659A1 (en) | 2019-08-08 |
| CN111655699A (en) | 2020-09-11 |
| US11319310B2 (en) | 2022-05-03 |
| EA202091804A1 (en) | 2020-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276145A (en) | Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors | |
| IL292642A (en) | Ras inhibitors | |
| IL292643A (en) | Ras inhibitors | |
| IL276137A (en) | Heterocyclyl-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors | |
| IL292644A (en) | Ras inhibitors | |
| IL278116A (en) | Pyridazinones as parp7 inhibitors | |
| ZA202003778B (en) | Heterocyclic compounds as prmt5 inhibitors | |
| RS61937B1 (en) | Oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors | |
| IL276269A (en) | Aminopyrrolotriazines as kinase inhibitors | |
| ZA201705675B (en) | Ghrelin o-acyl transferase inhibitors | |
| ZA201705678B (en) | Ghrelin o-acyl transferase inhibitors | |
| IL279453B (en) | Pyrazole derivatives as malt1 inhibitors | |
| SG11202005112TA (en) | Heterocyclic compounds as prmt5 inhibitors | |
| EP3684772C0 (en) | Cyclic iminopyrimidine derivatives as kinase inhibitors | |
| IL279452B (en) | Pyrazole derivatives as malt1 inhibitors | |
| IL277518A (en) | Substituted imidazolidin-2-one derivatives as prmt5 inhibitors | |
| ZA201908372B (en) | Pyridoquinazoline derivatives useful as protein kinase inhibitors | |
| GB201807845D0 (en) | Kinase Inhibitors | |
| GB201914388D0 (en) | Kinase inhibitors |